Baidu
map

J Allergy Clin Immunol:鼻息肉慢性鼻窦炎患者中免疫球蛋白G能够调控促炎性lgE响应

2019-03-01 AlexYang MedSci原创

鼻息肉慢性鼻窦炎(CRSwNP)通常可以通过多克隆lgE个体基因型的局部产生来鉴定。虽然组织lgE浓度能够达到几千kU/L,鼻息肉中lgE调节的炎症是通过怎样的机制来调控的仍旧不清楚。最近,有研究人员探索了是否鼻息肉中局部诱导的lgG抗体能够抑制lgE调节的促炎性响应。研究人员从草花粉过敏的CRSwNP和非过敏性对照受试者中采集了鼻息肉匀浆。研究发现,鼻息肉中,lgG在控制lgE调节的炎症响应方面

鼻息肉慢性鼻窦炎(CRSwNP)通常可以通过多克隆lgE个体基因型的局部产生来鉴定。虽然组织lgE浓度能够达到几千kU/L,鼻息肉中lgE调节的炎症是通过怎样的机制来调控的仍旧不清楚。

最近,有研究人员探索了是否鼻息肉中局部诱导的lgG抗体能够抑制lgE调节的促炎性响应。研究人员从草花粉过敏的CRSwNP和非过敏性对照受试者中采集了鼻息肉匀浆。研究发现,鼻息肉中,lgG在控制lgE调节的炎症响应方面具有关键的作用。鼻肉匀浆中lgG的缺失能够导致CD23调节的lgE促进性过敏原与B细胞结合的增加(lgE-FAB),同时提高了的FcεRI调节的过敏原能够驱使嗜碱性细胞的激活和组胺释放。研究人员在特异性lgE抗体对金黄色酿脓葡萄球菌(SE-lgE)中观察到乐儿相似的响应。另外,在过敏性和非过敏性鼻炎受试者中,鼻息肉中lgG限制lgE调节炎症的能力是基于lgG与lgE广泛的使用相同的抗原靶标。

最后,研究人员指出,CRSwNP中的lgE多克隆基因型是具有功能的,能够促进lgE调节的促过敏性炎症,并且与lgG存在部分的拮抗作用。

原始出处:

Shamji MH, Thomsen I, Layhadi J et al. Broad Immunglobulin G Repertoire in Chronic Rhinosinusitis with Nasal Polyps regulates pro-inflammatory IgE responses. J Allergy Clin Immunol. 11 Feb 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690055, encodeId=26401690055db, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Fri May 10 20:06:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035189, encodeId=c97d203518936, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jul 05 23:06:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283900, encodeId=66011283900e5, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329213, encodeId=fc98132921328, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351394, encodeId=b9ec1351394f4, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539215, encodeId=43c6153921563, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690055, encodeId=26401690055db, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Fri May 10 20:06:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035189, encodeId=c97d203518936, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jul 05 23:06:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283900, encodeId=66011283900e5, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329213, encodeId=fc98132921328, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351394, encodeId=b9ec1351394f4, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539215, encodeId=43c6153921563, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-07-05 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690055, encodeId=26401690055db, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Fri May 10 20:06:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035189, encodeId=c97d203518936, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jul 05 23:06:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283900, encodeId=66011283900e5, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329213, encodeId=fc98132921328, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351394, encodeId=b9ec1351394f4, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539215, encodeId=43c6153921563, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690055, encodeId=26401690055db, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Fri May 10 20:06:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035189, encodeId=c97d203518936, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jul 05 23:06:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283900, encodeId=66011283900e5, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329213, encodeId=fc98132921328, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351394, encodeId=b9ec1351394f4, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539215, encodeId=43c6153921563, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-03 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690055, encodeId=26401690055db, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Fri May 10 20:06:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035189, encodeId=c97d203518936, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jul 05 23:06:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283900, encodeId=66011283900e5, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329213, encodeId=fc98132921328, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351394, encodeId=b9ec1351394f4, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539215, encodeId=43c6153921563, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1690055, encodeId=26401690055db, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Fri May 10 20:06:00 CST 2019, time=2019-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035189, encodeId=c97d203518936, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jul 05 23:06:00 CST 2019, time=2019-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283900, encodeId=66011283900e5, content=<a href='/topic/show?id=ce1b2908938' target=_blank style='color:#2F92EE;'>#免疫球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29089, encryptionId=ce1b2908938, topicName=免疫球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=560d188, createdName=nymo, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329213, encodeId=fc98132921328, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351394, encodeId=b9ec1351394f4, content=<a href='/topic/show?id=be7453e38d2' target=_blank style='color:#2F92EE;'>#慢性鼻窦炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53738, encryptionId=be7453e38d2, topicName=慢性鼻窦炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539215, encodeId=43c6153921563, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Mar 03 13:06:00 CST 2019, time=2019-03-03, status=1, ipAttribution=)]
    2019-03-03 HNYYM

相关资讯

PLoS One:过敏性鼻炎儿科患者的急性鼻窦炎群体研究

虽然慢性鼻窦炎是过敏性鼻炎的常见并发症,而急性鼻窦炎与过敏性鼻炎之间的联系不清楚。最近,有研究人员利用基于群体的健康研究数据评估了患有过敏性鼻炎儿科患者的急性鼻窦炎发生率。研究包括了新诊断的年龄在5-18岁的过敏性鼻炎患者,并通过性别、年龄和年份指数匹配构建了一个比较群体。研究人员对所有的患者进行了跟踪调查,直到急性鼻窦炎诊断或者跟踪调查结束为止,并利用Cox比例风险模型评估了过敏性鼻炎和急性鼻窦

Int Forum Allergy Rhinol:11年之间中国鼻息肉慢性鼻窦炎患者的临床和组织特性变化

传统上认为,中国鼻息肉慢性鼻窦炎(CRSwNP)患者要比北美和欧洲患者具有更少的嗜酸性细胞和更多的中性粒细胞炎症。然而,炎症模式可能随着时间而变化。最近,有研究人员分析了中国患者CRSwNP临床和组织特性随着时间变化的趋势情况。研究包括了2003年到2005年间的115名连续性CRSwNP患者和2014年到2016年114名连续性CRSwNP患者。研究发现,在11年研究期间,嗜酸性粒细胞在鼻息肉组

Med Sci Monit:感官性听力损失与外毛细胞损伤引起的慢性鼻窦炎有关吗?

感官听力损失石油内耳的缺陷引起。研究中,研究人员调查了慢性鼻窦炎、外毛细胞损伤和感官听力损失之间的相关性。研究包括了103符合入选标砖的患者,并且分配到慢性鼻窦炎组(n=82)和单纯鼻中隔偏曲组(n=21)。研究发现,听力损失在单纯鼻中隔偏曲组中的比例要显著比慢性鼻炎组更低(4.76%, 1/21 vs. 24.39%, 20/82, P<0.05),其中15名慢性鼻窦炎患者(75%,15/

J Clin Med:肖格伦综合征与慢性鼻窦炎患者的相关性分析

最近,有研究人员调查了慢性鼻窦炎(CRS)风险在肖格伦综合征(SS)患者中的情况。研究包括了18723名患有SS的患者,时间为1997年和2011之间。更多的是,59568名不患有SS的患者与患有SS的患者在性别、年龄、城市化水平、收入水平和鼻炎并发症以及鼻中隔偏曲匹配的比例为1:4。主要结果为CRS的发生率。研究发现,CRS在患有SS的患者中的累积发生率要比那些没有患SS的患者显著更高(p<

Allergy Asthma Immunol Res:慢性鼻窦炎不同亚型中鼻组织特征性细胞因子研究

慢性鼻窦炎(CRS)的内分型在过去十年已经建立。然而,CRS准确的免疫情况仍旧还存在矛盾,原因是其具有很多的免疫异质性。因此,最近有研究人员根据慢性鼻窦炎不同鼻组织调查了不同的免疫调节因子情况,并做了相关比较。研究人员从对照、不具有NP的CRS患者(CRSsNP)和具有NP的CRS患者(CRSwNP)中分别搜集了钩突粘膜(UP)和鼻息肉(NP)组织。研究发现,在嗜酸性NP患者中,特征性炎症调控因子

J Allergy Clin Immunol:慢性鼻窦炎在普通人群中的患病率调查

慢性鼻窦炎在流行病学研究中的患病率为5-12%。但是由于与其他疾病,比如过敏性鼻炎重叠,因此该数据的评估可能偏高。最近,有研究人员根据EPOS(欧洲关于鼻窦炎和鼻息肉的文件)和鼻窦浑浊影像学,对基于CRS的流行病学患病率进行了评估。研究人员对那些经历了脑部CT或者MRI的受试者进行了相关调查,包括填写GA2LEN调查(包含EPOS症状标准)。研究人员根据Lund-Mackay (LM)评分系统对扫

Baidu
map
Baidu
map
Baidu
map